Immune system desensitization via regulatory T cell induction

Immune system desensitization via regulatory T cell induction refers to a process or treatment strategy aimed at *tolerizing* the immune response—particularly in situations of hypersensitivity, allergy, autoimmunity, or drug reactions—by *expanding or inducing antigen-specific regulatory T cells (Tregs)*[1][2][4][5]. Regulatory T cells, primarily identified as CD4+CD25+FOXP3+ cells, function to suppress excessive or undesired immune responses through direct cell-cell contact and/or secretion of suppressive cytokines, including IL-10, TGF-β, and IL-35[2][5]. Desensitization procedures, such as drug desensitization protocols, are believed to work in part by increasing the number and/or function of Tregs, which in turn suppress anti-drug antibody formation and reduce cellular hypersensitivity[1]. This is not a single molecular target but a therapeutic immunomodulatory approach involving multiple cell types and molecular pathways. Summary: "Immune system desensitization via regulatory T cell induction" describes a therapeutic process, not a discrete molecular or receptor target. It encompasses the clinical use of Treg induction to achieve immune tolerance, especially in allergy, autoimmunity, and desensitization protocols for biologic drugs[1][2][4][5].

Other names

Desensitization via Treg inductionImmune tolerance induction by regulatory T cellsTreg-mediated immune desensitization

Expansion or induction of antigen-specific regulatory T cells (Tregs), especially CD4+CD25+FOXP3+ subsets Secretation of immunosuppressive cytokines such as IL-10, TGF-β, and IL-35 causing downregulation of immune effector responses[1][2][4][5] Suppression of effector T-cell proliferation and cytokine production Reduction of anti-drug antibody titers and prevention of hypersensitivity reactions[1]